Low-renin hypertension (LRH) is a frequent condition in patients with arterial hypertension, accounting for 30% of patients. Monogenic forms can cause LRH in a minority of cases. However, in the large majority of patients, LRH is caused by the combined effects of congenital and acquired factors, comprising dietary habits. Several genetic variants have been proposed as co-factors in the pathogenesis of LRH with normal-low serum aldosterone. Emerging evidences support the hypothesis that a large proportion of LRH with normal-high serum aldosterone is associated with subclinical primary aldosteronism (PA). The recent identification of aldosterone-producing cell clusters (APCCs) as the possible cause of subclinical PA, further supported the concept of a continuous spectrum of autonomous aldosterone secretion, from subclinical forms towards overt PA. In this review we describe the main aspects of LRH, focusing on molecular basis, clinical risk profile and patients’ management.
The spectrum of low-renin hypertension
Buffolo F.First
;Monticone S.;Pecori A.;Pieroni J.;Losano I.;Cavaglia G.;Tetti M.;Veglio F.;Mulatero P.
Last
2020-01-01
Abstract
Low-renin hypertension (LRH) is a frequent condition in patients with arterial hypertension, accounting for 30% of patients. Monogenic forms can cause LRH in a minority of cases. However, in the large majority of patients, LRH is caused by the combined effects of congenital and acquired factors, comprising dietary habits. Several genetic variants have been proposed as co-factors in the pathogenesis of LRH with normal-low serum aldosterone. Emerging evidences support the hypothesis that a large proportion of LRH with normal-high serum aldosterone is associated with subclinical primary aldosteronism (PA). The recent identification of aldosterone-producing cell clusters (APCCs) as the possible cause of subclinical PA, further supported the concept of a continuous spectrum of autonomous aldosterone secretion, from subclinical forms towards overt PA. In this review we describe the main aspects of LRH, focusing on molecular basis, clinical risk profile and patients’ management.File | Dimensione | Formato | |
---|---|---|---|
Best Pract Res Clin Endocrinol Metab 2020 - 2nd submission.docx
Accesso riservato
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
132.98 kB
Formato
Microsoft Word XML
|
132.98 kB | Microsoft Word XML | Visualizza/Apri Richiedi una copia |
Figure 1 rev Best Pract.tif
Open Access dal 30/06/2020
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
4.98 MB
Formato
TIFF
|
4.98 MB | TIFF | Visualizza/Apri |
Best Pract Res Clin Endocrinol Metab 2020 - 2nd submission.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
318.65 kB
Formato
Adobe PDF
|
318.65 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.